ECEESPE2025 Poster Presentations Adrenal and Cardiovascular Endocrinology (169 abstracts)
Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (Cushing syndrome)
Corin Badiu 1 , Richard Auchus 2 , Irina Bancos 3 , Ulrich Dischinger 4 , Amir Hamrahian 5 , Alexandra Kautzky-Willer 6 , Miguel Angel Mangas-Cruz 7 , Cary N Mariash 8 , John Parker 9 , Rosario Pivonello 10 , Aurelian E Ranetti 11 , Gadi Shlomai 12 , Jeffrey Botbyl 13 , Andreas G Moraitis 13 & Katherine Araque 13
1“Carol Davila” University of Medicine and Pharmacy and National Institute of Endocrinology, Bucharest, Romania; 2Division of Metabolism, Diabetes, and Endocrinology, University of Michigan, Ann Arbor, MI, USA; 3Division of Endocrinology and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 4Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital of Würzburg, Würzburg, Germany; 5Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD, USA; 6Medizinische Universität Wien, Wien, Austria; 7Hospital Universitario Virgen del Rocio, Sevilla, Spain; 8Indiana University, Carmel, IN, USA; 9Accellacare Clinical Research, Wilmington Health Endocrinology, Wilmington, NC, USA; 10Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione Università Federico II di Napoli, Naples, Italy; 11Central Military University Emergency Hospital “Carol Davila”, Bucharest, Romania; 12Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel Aviv Faculty of Medicine, Ramat Gan, Israel; 13Corcept Therapeutics, Incorporated, Redwood City, CA, USA
JOINT1534
In the phase 3 GRACE study, treatment with the selective glucocorticoid receptor modulator relacorilant improved blood pressure and other cortisol-related comorbidities in patients with endogenous hypercortisolism. The objective of this phase 3 open-label extension study (OLE, NCT03604198) was to assess the long-term efficacy and safety of relacorilant. Patients were eligible to enter the OLE if they completed a Corcept-sponsored parent relacorilant study, including either GRACE (NCT02804750), GRADIENT (NCT03697109), or the phase 2 study (NCT04308590), and in the investigator’s opinion, might benefit from further treatment. As of September 8, 2024, there were 116 patients enrolled in the OLE. Patients’ blood pressure continued to improve during relacorilant treatment. The mean (standard deviation) change in systolic and diastolic blood pressure from OLE baseline to month 24 was −10.0 [9.51] mmHg (P=0.012) and −7.3 [7.36] mmHg (P=0.016), respectively. Daytime and nighttime blood pressure also improved during the OLE. In GRACE, patients who switched to placebo during the randomized-withdrawal phase experienced a deterioration in blood pressure. When relacorilant treatment was resumed in the OLE, their blood pressure improved. Improvements in body weight, glycemic control, and other cortisol-related comorbidities that were observed in the GRACE study were maintained in the OLE. Relacorilant was well tolerated in the OLE, consistent with the parent studies. No new safety signals were identified during up to 6 years of treatment. Long-term treatment with relacorilant led to significant and durable cardiometabolic improvements in patients with hypercortisolism and was well-tolerated.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more